Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

Corneel Coens(European Organisation for Research and Treatment of Cancer), Alexander M.M. Eggermont(University Medical Center Utrecht), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Virginia Ferraresi(Cancer Institute (WIA)), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Veerle de Pril(Inserm), Henrik Schmidt(Aarhus University Hospital), Stefan Suciu(St James's University Hospital), Jon Richards(Oncology Specialists), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Andrew Bottomley(Bradford Teaching Hospitals NHS Foundation Trust), Jean-Jacques Grob(Aix-Marseille Université), Michael Smylie(Inserm), Srividya Kotapati(Bristol-Myers Squibb (United States)), Michele Maio(University of Siena)

The Lancet Oncology

February 3, 2017

Cited by 104

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Oncology|2009|4.6k

Related Papers